Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Institut Claudius Regaud
Sichuan Baili Pharmaceutical Co., Ltd.
BioNTech SE
Peking University Cancer Hospital & Institute
ImmunoGenesis
Beijing Biostar Pharmaceuticals Co., Ltd.
Genentech, Inc.
Jiangsu HengRui Medicine Co., Ltd.
InxMed (Shanghai) Co., Ltd.
3D Medicines
InxMed (Shanghai) Co., Ltd.
TCRCure Biopharma Ltd.
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
BeOne Medicines
Prisma Health-Upstate
Servier
Children's National Research Institute
M.D. Anderson Cancer Center
Mabwell (Shanghai) Bioscience Co., Ltd.
Novartis
Biohaven Pharmaceuticals, Inc.
Chugai Pharmaceutical
Anhui Provincial Cancer Hospital
Sichuan Huiyu Pharmaceutical Co., Ltd
Georgetown University
Salubris Biotherapeutics Inc
Peking University Cancer Hospital & Institute
Eisai Inc.
Emory University
St. Jude Children's Research Hospital
Zhejiang University
Memorial Sloan Kettering Cancer Center
Advenchen Laboratories, LLC
Innovent Biologics Technology Limited (Shanghai R&D Center)
Binhui Biopharmaceutical Co., Ltd.
Axcynsis Therapeutics Pte Ltd
Suzhou Biomissile Pharmaceuticals Co., Ltd.
Gilead Sciences
Memorial Sloan Kettering Cancer Center
TCRCure Biopharma Ltd.
Nuvation Bio Inc.
Sanofi